Dipexium effected a reverse stock split of its issued and outstanding shares of common stock at a ratio of 1-for-8. The holders of shares of PLx common stock outstanding immediately prior to the merger received, as merger consideration, …
PLx stockholders will receive newly issued shares of common stock of Dipexium in connection with the merger contemplated by the merger agreement. Dipexium will issue approximately 36 million new shares of its common stock
Protalix BioTherapeutics, Inc. (NYSE: PLX) announced the entry into a definitive exchange ... approximately 23.8 …
As follows, the stock traded $4.70 higher at $57.42 for over 7% profits ... (FOLD), Ultragenyx (RARE), Sparks Therapeutics (ONCE), Protalix Biotherapeutics (PLX), and Solid Biosciences (SLDB). In all, Crispr topped our list as the most …
One stock that might be an intriguing choice for investors right now is Protalix BioTherapeutics, Inc. (PLX). This is because this security in the Biotechnology space is seeing solid earnings estimate revision activity, and is in great company …
One thing he thinks investors are missing is that the company’s revenue growth, not including acquisitions, has been better than people think: We deconstructed …
Aspertec 325 mg and Aspertec 81 mg (referred to together as Aspertec), has completed its previously announced merger with Dipexium Pharmaceuticals, Inc. (Dipexium), effective as of April 19, 2017. The combined companywhich …
PLX closed Thursday's trading at 0.55, down 3.48%. In after-hours, the stock was up 11.71% to $0.64. ZELTIQ Aesthetics Inc.'s (ZLTQ) fat freezing method CoolSculpting has now received FDA clearance to address another body area - upper …